Shares GRAIL, INC. COMMON STOCK, $0.001 PAR VALUE PER SHARE UNDERWRITING AGREEMENTGrail, Inc. • September 17th, 2020 • Services-medical laboratories • New York
c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o Cowen and Company, LLC 599 Lexington Avenue, 25th Floor New York, New York 10022 c/o Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055
Certain information (indicated by asterisks) has been omitted from this document because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed. DATED 7th April 2016 and LICENCE AGREEMENTLicence Agreement • September 9th, 2020 • Grail, Inc. • Services-medical laboratories • Hong Kong
(1)The Chinese University of Hong Kong, a university established by legislation in the Hong Kong Special Administrative Region (“Hong Kong SAR”) located in Shatin, New Territories, Hong Kong SAR acting in its capacity as the owner of the Invention as defined herein (“University”); and
FIRST AMENDMENT TO LEASELease • September 9th, 2020 • Grail, Inc. • Services-medical laboratories
THE FIRST AMENDMENT TO LEASE (this "Amendment") is dated as of June 8, 2017 and is among MENLO PREHC I, LLC, a Delaware limited liability company, MENLO PREPI I, LLC, a Delaware limited liability company, and TPI INVESTORS 9, LLC, a California limited liability company (collectively, "Lessor"), and GRAIL, INC., a Delaware corporation ("Lessee"), with respect to the following recitals:
SEPARATION AND GENERAL RELEASE AGREEMENTSeparation and General Release Agreement • September 9th, 2020 • Grail, Inc. • Services-medical laboratories • California
THIS SEPARATION AND GENERAL RELEASE AGREEMENT (the "Agreement") is entered into as of the first date on the signature page hereto by and between GRAIL, Inc., a Delaware corporation (the "Company"), and Jennifer Cook ("you") (together, the "Parties").
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • September 9th, 2020 • Grail, Inc. • Services-medical laboratories • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 27th day of November, 2019, by and among GRAIL, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 7.9 hereof, and amends and restates, in its entirety, the Amended and Restated Investors’ Rights Agreement (the “Prior Agreement”), dated as of May 16, 2018, by and among the Company and certain of the Investors.
STOCK PURCHASE AGREEMENT by and among GRAIL, INC., a Delaware corporation, CIRINA LIMITED, a company established under the laws of the Hong Kong Special Administrative Region, THE COMPANY STOCKHOLDERS and SHAREHOLDER REPRESENTATIVE SERVICES LLC, as...Stock Purchase Agreement • September 9th, 2020 • Grail, Inc. • Services-medical laboratories • Delaware
This STOCK PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of May 30, 2017 (the “Agreement Date”), by and among GRAIL, Inc., a Delaware corporation (“Purchaser”), Cirina Limited, a company established under the laws of the Hong Kong Special Administrative Region (the “Company”), the Company Stockholders listed on Exhibit A hereto (the “Initial Selling Stockholders”)) and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the representative of the Company Securityholders hereunder (the “Equityholders’ Representative”). Certain other capitalized terms used herein are defined in Exhibit B. The Company was founded by Yuk Ming Dennis Lo, Wai Kwun Rossa Chiu and Kwan Chee Chan with the long-term vision to reduce mortality in cancer through cutting-edge research and development into cancer screening, monitoring and prognostication, and thus the original intention in the establishment of Cirina Limited follows the same lon
and LICENCE AGREEMENTLicence Agreement • September 9th, 2020 • Grail, Inc. • Services-medical laboratories • Hong Kong
STOCK OPTION AGREEMENTStock Option Agreement • September 9th, 2020 • Grail, Inc. • Services-medical laboratories • California
This Stock Option Agreement (this “Agreement”) is made and entered into as of the date of grant (the “Date of Grant”) set forth on the Notice of Stock Option Grant attached as the facing page to this Agreement (the “Grant Notice”) by and between GRAIL, Inc., a Delaware corporation (the “Company”), and the optionee named on the Grant Notice (“Optionee”). Capitalized terms not defined in this Agreement shall have the meaning ascribed to them in the Company’s 2016 Equity Incentive Plan, as amended from time to time (the “Plan”), or in the Grant Notice, as applicable.
LEASE AGREEMENTLease Agreement • September 9th, 2020 • Grail, Inc. • Services-medical laboratories • North Carolina
THIS LEASE AGREEMENT is executed this 4th day of June, 2020, (the “Lease Date”), by and between PP OFFICE OWNER 1, L.P., a Delaware limited partnership (“Landlord”), and GRAIL, INC., a Delaware corporation (“Tenant”).
CONSULTING AGREEMENTConsulting Agreement • September 9th, 2020 • Grail, Inc. • Services-medical laboratories • California
This Consulting Agreement (“Agreement”) is made as of May 10, 2016 (“Effective Date”), by and between Grail, Inc., a Delaware corporation (“Company”), and Richard Klausner (“Consultant”).
TRANSITION AGREEMENTTransition Agreement • September 9th, 2020 • Grail, Inc. • Services-medical laboratories • California
This Transition Agreement (this “Agreement”) is made and entered into as of October 12, 2017, by and between GRAIL, Inc., a Delaware corporation (the “Company”), and Jeffrey T. Huber (“you”).
TRANSITION AGREEMENTTransition Agreement • July 31st, 2020 • Grail, Inc. • Services-medical laboratories • California
This Transition Agreement (this “Agreement”) is made and entered into as of October 12, 2017, by and between GRAIL, Inc., a Delaware corporation (the “Company”), and Jeffrey T. Huber (“you”).
Detect cancer early, when it can be cured.Grail, Inc. • September 9th, 2020 • Services-medical laboratories
As you know, you and GRAIL, Inc. (the “Company”) are parties to an offer letter agreement, dated November 15, 2019 (the “Prior Offer Letter”), which sets forth the terms of your current employment arrangement with the Company.
